Blood Journal
Leading the way in experimental and clinical research in hematology

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

  1. Simon J. Harrison13,
  2. Hang Quach25,
  3. Emma Link6,
  4. John F. Seymour1,2,
  5. David S. Ritchie13,
  6. Sam Ruell7,
  7. Joanne Dean6,
  8. Henry Januszewicz1,
  9. Ricky Johnstone2,8,
  10. Paul Neeson3,
  11. Michael Dickinson1,2,
  12. Jean Nichols9, and
  13. H. Miles Prince14
  1. 1Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia;
  2. 2University of Melbourne, Melbourne, Australia;
  3. 3Haematology Immunology Translational Research Laboratory, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia;
  4. 4Faculty of Medicine, Monash University, Victoria, Australia;
  5. 5Haematology Service, Monash Medical Centre, Melbourne, Australia;
  6. 6Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Australia;
  7. 7Clinical Trials Unit, Peter MacCallum Cancer Centre, East Melbourne, Australia;
  8. 8Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia; and
  9. 9Celgene Corporation, Summit, NJ

To view this item, select one of the options below

If you already have a subscription, you may gain access using your ASH username and password.

Sign In for Institutional Administrators

If you are a Librarian or institutional account administrator you can use this link to manage your account and view usage reports.

 

Purchase Short-Term Access

Pay per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00.
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

OpenAthens Users

Log in through your institution

Sign Up

Subscribe to the Journal - Subscribe to the print and/or online journal.

Access for Patients

Access for Patients - Patients desiring access should contact the journal.